MARKET

SLN

SLN

Silence Therapeutics Plc
NASDAQ
3.910
-0.150
-3.69%
After Hours: 4.190 +0.28 +7.16% 17:37 03/14 EDT
OPEN
4.060
PREV CLOSE
4.060
HIGH
4.240
LOW
3.900
VOLUME
148.84K
TURNOVER
--
52 WEEK HIGH
27.72
52 WEEK LOW
3.900
MARKET CAP
184.65M
P/E (TTM)
-3.9914
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLN last week (0303-0307)?
Weekly Report · 5d ago
Silence Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
Dow Jones · 03/07 12:09
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Benzinga · 03/07 11:59
Silence Therapeutics: Strategic Focus and Strong Financials Poised for Growth with Promising RNAi Pipeline
TipRanks · 03/07 11:28
Silence Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 03/05 14:19
Silence Therapeutics Price Target Cut to $45.00/Share From $49.00 by Morgan Stanley
Dow Jones · 03/05 14:19
Morgan Stanley Maintains Overweight on Silence Therapeutics, Lowers Price Target to $45
Benzinga · 03/05 14:08
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
Benzinga · 03/04 21:01
More
About SLN
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.

Webull offers Silence Therapeutics PLC - ADR stock information, including NASDAQ: SLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLN stock methods without spending real money on the virtual paper trading platform.